Business continues to boom for US biotechnology firm Moderna, thanks to its sought-after coronavirus vaccine. In the first quarter of 2022, revenues rose by around 220% year-on-year to $6.1 billion, the company announced in Cambridge on Wednesday. Net income stood at $3.7 billion – more than three times as much as a year ago. The pharmaceutical manufacturer kept its sales forecast for its coronavirus vaccine unchanged. For the 2022 financial year, Moderna expects its vaccine to generate revenues of around $21 billion, based on sales agreements already made. The quarterly report clearly exceede…